OBI Pharma
OBI Pharma is a Taipei-based, Taipei Exchange-listed clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer using its proprietary Obrion® platform (GlycOBI®, ThiOBI®, HYPrOBI®), generating revenue through licensing and partnerships with global pharma rather than product sales.
- Company typePublic
- Founded2002
- HeadquartersTaipei, Taiwan
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What OBI Pharma does
OBI Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Taipei, Taiwan and listed on the Taipei Exchange (4174.TWO). Founded in 2002, the company has refocused its strategy on developing antibody-drug conjugates (ADCs) for cancer treatment, following the 2025 termination of its earlier Globo H immunotherapy programs. OBI serves two principal customer segments: (i) cancer patients with solid tumors and hematological malignancies targeted through OBI's clinical-stage drug candidates, and (ii) global pharmaceutical partners who license OBI's ADC products and platform technologies for co-development or commercialization.
OBI's core technology is the Obrion® ADC Technology Platform, a modular system for next-generation drug conjugation built around five proprietary sub-platforms: GlycOBI® (glycan site-specific conjugation), GlycOBI DUO® (dual-payload conjugation), ThiOBI® (cysteine-based conjugation for nanobodies, fragments, and peptides), EndoSymeOBI® (proprietary enzymatic glycan remodeling), and HYPrOBI® (hydrophilic linker with masking and shielding effects). Together these enable site-specific, homogenous ADC generation with tunable drug-to-antibody ratios from DAR2 to DAR16. The clinical pipeline targets validated oncology biomarkers including TROP2 (OBI-992, OBI-902), Nectin-4 (OBI-904), HER2, cMET, and HER3, with OBI-992 in Phase I/II and OBI-902 having entered Phase I/II in August 2025. Several candidates have received FDA Orphan Drug Designations.
OBI generates revenue exclusively through licensing royalties, one-time license fees, and collaboration payments, as it has no commercialized products. The company is publicly traded, has approximately 140 employees, and operates through wholly- or majority-owned subsidiaries in the US (OBI Pharma USA, Inc.) and Australia (OBI Pharma Australia Pty Ltd), as well as majority-owned biotech and cosmetic-medicine entities (Amaran Biotechnology, Obigen Pharma, AP Biosciences). Recent licensing and collaboration deals with TegMine Therapeutics, AP Biosciences, GlyTech, Ascentawits, and Zhejiang Hisun Pharmaceutical demonstrate a partnership-led commercialization model across North America, Greater China, and Japan.
OBI Pharma firmographics
Firmographics- Name
- OBI Pharma
- Legal name
- OBI Pharma, Inc.
- Website
- https://obipharma.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- OBI Pharma is a Taipei-based, Taipei Exchange-listed clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for cancer using its proprietary Obrion® platform (GlycOBI®, ThiOBI®, HYPrOBI®), generating revenue through licensing and partnerships with global pharma rather than product sales.
- Ownership category
- akta.pro rank
OBI Pharma industry classification
Industry- Product category
- Oncology Biopharmaceuticals (Antibody-Drug Conjugates)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
Keywords
Where OBI Pharma is headquartered
LocationHeadquarters
- HQ city
- Taipei
- HQ country
- Taiwan
- HQ region
- Asia
Offices3 records
Markets served
OBI Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing and Collaboration Revenue: OBI Pharma generates revenue through out-licensing its ADC products and proprietary platform technologies to global pharmaceutical partners. The company has signed licensing agreements with partners including TegMine Therapeutics for glycan-targeting ADC, and maintains collaboration agreements with AP Biosciences and others.
- No Commercialized Products: As a clinical-stage oncology company, OBI Pharma has no commercialized products generating revenue. All products are in development stage (preclinical through Phase 2).
Go-to-market motion1 record
Marketing channels5 records
OBI Pharma product offering
Product offeringCore offering
OBI Pharma is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and prodrugs for oncology indications. Its proprietary Obrion® ADC platform and sub-platforms (GlycOBI®, GlycOBI DUO®, ThiOBI®, EndoSymeOBI®, HYPrOBI®) enable site-specific conjugation and controlled DAR for homogeneous ADCs. Lead programs include OBI-992, OBI-902 (TROP2 ADCs), OBI-3424 (AKR1C3 prodrug), OBI-999 and OBI-888 (Globo H ADCs).
Differentiator
Problem solved
Functional benefit
Products and services
- OBI-992 TROP2-targeted antibody-drug conjugate in clinical development by OBI Pharma for oncology indications.
- OBI-902 TROP2-targeted antibody-drug conjugate in clinical development by OBI Pharma for oncology indications.
- OBI-3424 AKR1C3-activated prodrug (small molecule) in clinical development by OBI Pharma for oncology indications.
- OBI-999 Globo H-targeted antibody-drug conjugate developed by OBI Pharma for oncology indications.
- OBI-888 Globo H-targeted antibody-drug conjugate developed by OBI Pharma for oncology indications.
- Obrion® ADC Technology Platform (including GlycOBI®, GlycOBI DUO®, ThiOBI®, EndoSymeOBI®, HYPrOBI® sub-platforms) Proprietary modular ADC technology platform offered by OBI Pharma for licensing to global pharmaceutical partners, enabling site-specific conjugation, controlled DAR, and improved ADC stability.
Quantifiable outcome
- OBI-992 reached putative Recommended Phase 2 Dose (pRP2D) in Phase 1/2 study
- +2 more outcomes
Companies that use OBI Pharma
Customer profileSegments3 records
Ideal customer profiles1 record
OBI Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
OBI Pharma partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- TegMine TherapeuticscoreOBI Pharma signed an exclusive global license agreement with TegMine Therapeutics for a glycan-targeting ADC. This follows the successful delivery of a commissioned ADC candidate, advancing the collaboration between OBI and TegMine. OBI provides its GlycOBI® enabling technology while TegMine contributes antibodies targeting cancer-associated glycans.
- AP BiosciencescoreOBI Pharma signed a Material Transfer and Technology Development Agreement (MTA) with AP Biosciences to develop next-generation bispecific Antibody-Drug Conjugates (ADCs). AP Biosciences provides a bispecific antibody (BsAb) while OBI Pharma contributes its GlycOBI® glycan-conjugation technology platform.
- TegMine TherapeuticscoreOBI Pharma entered into a Master Services Agreement with TegMine Therapeutics for ADC-related collaboration. TegMine specializes in developing best-in-class antibodies targeting cancer glycans and glycoproteins. The collaboration utilizes OBI's GlycOBI® and TegMine's TegMiner™ enabling technologies.
- AscentawitscoreOBI-3424 is under clinical evaluation in collaboration with Ascentawits. Ascentawits has completed enrollment in a single-arm phase II trial in HCC and initiated a phase IIb study in HCC. OBI acquired worldwide rights from Threshold Pharmaceuticals except for rights in Taiwan, Japan, South Korea, Singapore, Malaysia, Thailand, Turkey, India which are owned by Ascentawits as AST-3424.
- GlyTechminorSigned marketing promotion and material transfer agreement with Japan's GlyTech for GlycOBI® ADC key technology in the Japanese market. GlyTech serves as a marketing promotion partner for OBI's technology platform in Japan.
- Ablexis, LLCcoreOBI Pharma licensed 'Nectin-4 Human Antibody' rights from Ablexis, LLC in 2023. This enables OBI's development of Nectin-4 targeted ADCs including OBI-904.
- Biosion, Inc.coreOBI signed an exclusive license agreement for anti-TROP2 humanized monoclonal antibody (BSI04702) with Biosion for worldwide rights excluding China, Hong Kong and Macao. OBI has licensed the TROP2 targeting antibody amino acid sequence since December 2021. OBI holds worldwide commercial rights to OBI-902 and OBI-992 except for rights pertaining to the antibody in China.
- Zhejiang Hisun Pharmaceutical Co. Ltd.coreCollaboration on OBI-3424/AST-3424 development in China. Zhejiang Hisun Pharmaceutical holds rights in China, Hong Kong, Macao for OBI-3424/AST-3424 and has initiated a phase IIb study in HCC in collaboration with Ascentawits.
Scale indicators3 records
Recent moves13 records
Expansion highlights6 records
OBI Pharma competitors and assessment
Company assessmentDirect peers
- ProfoundBio: Clinical-stage ADC company with proprietary conjugation technology and pipeline targeting validated oncology antigens (FRα, HER2, HER3). Closely comparable to OBI in pipeline architecture, antigen selection, and platform-based approach.
- Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating ADCs (ISACs), a related next-generation ADC category. Comparable in clinical stage, target oncology focus, and platform-technology licensing model.
- Pyxis Oncology: Clinical-stage ADC and antibody-drug conjugate developer with a pipeline targeting solid tumors. Closely comparable in stage, business model (out-licensing and platform partnerships), and focus on site-specific conjugation approaches.
- Mersana Therapeutics: Clinical-stage ADC developer with proprietary Dolasynthen and Immunosynthen platforms targeting oncology. Comparable as a similarly-sized clinical-stage biotech focused exclusively on next-generation ADC conjugation technologies with no commercialized products.
- Tubulis: Clinical-stage ADC biotech focused on differentiated conjugation chemistry and linker technologies, with lead candidates in solid tumors. Directly comparable on enabling-technology positioning and clinical-stage ADC focus.
Emerging players
- Innovent Biologics: China-headquartered biopharmaceutical company developing next-generation ADCs (IBI354, IBI130, IBI3001) with global out-licensing ambitions. Comparable as an Asia-based clinical-stage ADC developer with platform-out-licensing strategy.
- Hansoh Pharmaceutical: Chinese pharma with growing ADC pipeline and global BD ambitions (multiple licensing deals with big pharma in oncology). Comparable as an Asia-based emerging ADC developer pursuing similar out-licensing and partnership strategies.
Broad incumbents
- Daiichi Sankyo: Japanese pharma leader behind the DXd ADC platform (Enhertu, Datroway with AstraZeneca). Sets the competitive benchmark for site-specific ADCs that OBI's GlycOBI® platform competes against; relevant for licensing economics and partnership dynamics.
- Pfizer: Global pharma with major ADC franchise post-Seagen acquisition (Adcetris, Padcev, Tukysa, Tivdak). Competes directly for ADC licensing deals and represents a likely strategic acquirer or large-pharma partner for clinical-stage ADC developers.
- AstraZeneca: Global pharma with major ADC franchise via Daiichi Sankyo partnership (Enhertu, Datroway). Represents both a potential licensor/partner for OBI's platform and a competitor pursuing similar TROP2, HER2, and HER3 targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
OBI Pharma social profiles
Digital presenceOBI Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
OBI Pharma leadership team
Management profileNumber of profiles
Profiles7 records
OBI Pharma subsidiaries and ownership
Company hierarchySubsidiaries5 records
OBI Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OBI Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OBI Pharma
What does OBI Pharma do?
OBI Pharma is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and prodrugs for oncology indications. Its proprietary Obrion® ADC platform and sub-platforms (GlycOBI®, GlycOBI DUO®, ThiOBI®, EndoSymeOBI®, HYPrOBI®) enable site-specific conjugation and controlled DAR for homogeneous ADCs. Lead programs include OBI-992, OBI-902 (TROP2 ADCs), OBI-3424 (AKR1C3 prodrug), OBI-999 and OBI-888 (Globo H ADCs).
Is OBI Pharma a public or private company?
OBI Pharma is a public company. It is classified as public and is currently operating.
When was OBI Pharma founded?
OBI Pharma was founded in 2002. It employs 101 to 250 people.
Where is OBI Pharma based?
OBI Pharma is headquartered in Taipei, Taiwan, in the Asia region.
How does OBI Pharma make money?
Two revenue lines are on record. Licensing and Collaboration Revenue is the primary driver. The others are no Commercialized Products.
Who are OBI Pharma's main competitors?
Direct peers on record are ProfoundBio, Bolt Biotherapeutics, Pyxis Oncology, Mersana Therapeutics and Tubulis. Emerging players are Innovent Biologics and Hansoh Pharmaceutical. Broad incumbents are Daiichi Sankyo, Pfizer and AstraZeneca.
Does OBI Pharma have an API?
No public API is recorded for OBI Pharma.
What industry is OBI Pharma in?
OBI Pharma's product category is Oncology Biopharmaceuticals (Antibody-Drug Conjugates). Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 325414 and its SIC code is 2834.